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Allosteric cross-talk in chromatin can mediate
drug-drug synergy
Zenita Adhireksan1,*, Giulia Palermo2,*, Tina Riedel2,*, Zhujun Ma1,*, Reyhan Muhammad1, Ursula Rothlisberger2,
Paul J. Dyson2 & Curt A. Davey1,3
Exploitation of drug–drug synergism and allostery could yield superior therapies by capita-
lizing on the immensely diverse, but highly specific, potential associated with the biological
macromolecular landscape. Here we describe a drug–drug synergy mediated by allosteric
cross-talk in chromatin, whereby the binding of one drug alters the activity of the second. We
found two unrelated drugs, RAPTA-T and auranofin, that yield a synergistic activity in killing
cancer cells, which coincides with a substantially greater number of chromatin adducts
formed by one of the compounds when adducts from the other agent are also present.
We show that this occurs through an allosteric mechanism within the nucleosome, whereby
defined histone adducts of one drug promote reaction of the other drug at a distant, specific
histone site. This opens up possibilities for epigenetic targeting and suggests that allosteric
modulation in nucleosomes may have biological relevance and potential for therapeutic
interventions.
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T
herapies based on an individual drug frequently
have limited efficacy with poor resistance and safety
profiles1. This arises largely from the network basis of cell
structure and activity, whereby numerous interacting pathways
can potentially allow for compensation, counteraction or
neutralization of the initial drug effect. To circumvent these
shortcomings of single agent regimens, much effort has been
focusing on discovering drug combinations that function in
a therapeutically productive fashion. Combinations that act in
synergy can be especially advantageous by lowering therapeutic
dose, thereby diminishing off-site targeting and corresponding
side effects. In fact, synergistic drug combinations have been
shown to generally coincide with improved therapeutically
specific selectivity2.
The origin of a particular drug–drug synergy can be varied, but
commonly comes about via one of several general phenomena,
including complementing or facilitating actions or effects
that antagonize counteraction1. The molecular mechanism of
the synergy may thus arise from targeting different molecules
that do or do not interact over the course of the therapeutic
event. Alternatively, targeting of two different sites on a given
molecule or molecular assembly may underlie the synergy,
which raises the possibility that the drug–drug interaction is
mediated allosterically. In this scenario, there is no direct
interaction between the agents, but rather the binding of one
drug shifts the dynamic equilibrium of conformational substates
in such a way that it influences the association of the other drug3.
Largely because of the enormously diverse binding site and
conformational landscape available to allosteric modulation, it
has been argued that the discovery of allosterically acting drugs
has special potential for developing innovative therapies4. But the
challenge is first to uncover these compounds and second to
define the mechanism of action, allowing for rational design
strategies5. There are numerous examples of well-defined
allosteric drug mechanisms behind protein signalling systems,
in particular G protein-coupled receptors6 and different kinases7,
and also for a variety of drug metabolizing enzymes, the P450
cytochromes8. However, instances of allosteric drug activities on
the histone protein-packaged form of cellular DNA, chromatin,
are not clear, and chromatin drug–drug interactions of allosteric
origin have not been reported.
Here we characterize a synergistic impact on tumour cells
mediated by RAPTA-T, [(Z6-p-toluene)Ru(1,3,5-triaza-7-phosphaa-
damantane)Cl2], and auranofin, [3,4,5-triacetyloxy-6-acetyloxy-
methyl,oxane-2-thiolate)Au(triethylphosphanium)] (AUF; Fig. 1a).
RAPTA-T is a bifunctional ruthenium agent that displays low
toxicity and is proficient at inhibiting both primary tumour
growth and the spreading and growth of solid metastatic tumours
in mice9,10. This agent also has anti-angiogenic properties that
likely contribute to the antimetastasis activities11. AUF, on the
other hand, is a monofunctional gold compound having high
cytotoxicity, which was developed more than 30 years ago as an
orally administrable drug to treat rheumatoid arthritis12. However,
recent years have witnessed a resurgence of interest in AUF as
a potential anticancer or antimicrobial agent, since it has come
to light that it can inhibit both inflammatory pathways and thiol
redox enzymes13.
The cytotoxic effect of AUF towards cancer cells appears to
stem, at least in part, from targeting protein factors involved in
pro-inflammatory pathways that facilitate tumour growth
and development13. Although DNA has to our knowledge not
been reported as an AUF target, we had previously discovered
that certain metal-based compounds can form site-specific
adducts on the histone proteins that package DNA into
the basic repeating unit of chromatin, the nucleosome14–17.
We therefore investigated this as a possibility for AUF targeting
here and found that AUF and RAPTA-T both form histone
protein adducts in the nucleosome core, albeit at distantly related
sites. Moreover, the presence of RAPTA-T substantially facilitates
AUF adduct formation. This synergism elicited by RAPTA-T
and AUF appears to be mediated via an allosteric mechanism
within the nucleosome, which has biological implications
and may open up new avenues for drug development beyond
metal-based drugs.
Results
Tumour cell cytotoxicity synergism with RAPTA-T and AUF.
RAPTA-T has sufficiently low toxicity that treatment of human
ovarian cancer A2780 cells with a 30 mM concentration of the
compound yields no measurable impact on cell viability, whereas
the corresponding IC50 value for AUF is o100 nM (Fig. 1b).
However, when cells are treated with both RAPTA-T and AUF,
cell viability is reduced significantly relative to treatment with
AUF alone (Fig. 1b). The drug combination coincides with
a synergistic impact on viability, which is maximal (over the
concentration ranges tested) at approximately 62 mM RAPTA-T
(Fig. 1c). In addition, we found that there is a significantly greater
reduction in viability when cells are first pre-treated with
RAPTA-T followed by incubation with AUF as compared to vice
versa—pre-treatment with AUF, followed by incubation with
RAPTA-T (Supplementary Fig. 1). This indicates that RAPTA-T
activity has a sensitizing effect on the tumour cells towards AUF.
Synergistic accumulation of cellular chromatin drug adducts.
We next employed inductively coupled plasma mass spectro-
metry (ICP-MS) to quantify drug association with chromatin in
tumour cells. Treatment of cells with either RAPTA-T alone or
AUF alone resulted in substantial levels of chromatin-metal
adduct formation, 139±29 pmol per mg of DNA of ruthenium
and about twice that level of gold, 345±138 pmol per mg of DNA,
for the two individual compounds (Fig. 1d). When cells were
subsequently co-treated with RAPTA-T and AUF together, the
level of chromatin-bound ruthenium remained approximately
the same, to within experimental error, relative to the treatment
with RAPTA-T alone. However, this co-treatment yielded
a nearly threefold greater quantity, 1,006±324 pmol per mg of
DNA, of chromatin-bound gold relative to AUF treatment alone,
indicating that RAPTA-T promotes chromatin-AUF adduct
formation.
RAPTA-T forms specific histone adducts on the nucleosome.
To shed light on the chromatin site selectivity of RAPTA-T,
we treated nucleosome core particle (NCP) crystals with
the compound and characterized adduct formation by X-ray
crystallography (Supplementary Table 1; Supplementary Fig. 2).
RAPTA-T generates adducts, via substitution of the chloride
ligands, at two adjacent sites on the face of the nucleosome core
where a preponderance of glutamate and aspartate residues from
the histone H2A–H2B dimer form an ‘acidic patch’14–18, known
to be a key protein binding motif for chromatin regulation19–21
(Fig. 2). The two RAPTA-T binding sites, RU1 and RU2,
entail coordination of the ruthenium centre to the H2A E61 and
E64 carboxylate groups (RU1) and the imidazole and carboxylate
groups of H2B H106 and E102 (RU2). The close proximity of
the two sites coincides with a van der Waals (hydrophobic)
contact between the toluene ring of RU1 and the PTA ligand
of RU2.
Distinct histone site reactivity of AUF with RAPTA-T present.
We conducted NCP crystal treatment trials with AUF using the
same approach as for the derivatization with RAPTA compounds.
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However, even from extensive treatments entailing 1mM AUF in
the buffer with an incubation time of up to 4 days, we found no
evidence of gold adduct formation in the crystals (Supplementary
Table 2). Since diffraction data were collected at the X-ray
absorption edge of gold, sites of gold binding even at low
occupancy can be detected.
We next conducted co-treatment trials with RAPTA-T
and AUF simultaneously present in the treatment buffer and
observed that both ruthenium and gold adducts are generated
readily at distinct histone sites (Supplementary Tables 2 and 3;
Supplementary Fig. 3). The RAPTA-T adducts form at the same
two adjacent locations observed for the RAPTA-T only
treatments, RU1 and RU2, whereas AUF generates adducts at
two symmetry-related locations, AU1 and AU10, which are
not far from the central base pair and situated along the
twofold axis of the nucleosome (Fig. 3a,b). The gold ions are
coordinated to the imidazole delta nitrogen atoms of H113 and
H1130 from the two H3 histone proteins. The AUF sugar-thiolate
groups have been substituted by the histone ligands, and the
Au-triethylphosphine units fill a narrow, but shallow, access
channel to the exposed nitrogen groups of the histidine side
chains (Fig. 3c). The triethylphosphine groups make extensive
hydrophobic contacts with surrounding H3 residues, which
entail interactions with both copies of H3 for a given adduct.
RAPTA-T adducts alter nucleosome conformational properties.
The requirement for the presence of both RAPTA-T and AUF in
the NCP treatments to allow gold adduct formation at AU1 and
AU10 suggests that the RAPTA-T adducts promote reactivity
of the H3/H30 H113 sites. However, the closest distance between
any two adduct atoms of RU1/RU2 and AU1/AU10 is 27Å
(Fig. 3a; Supplementary Movie 1). Although no large confor-
mational differences are observed between any of the three
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Figure 1 | Synergistic activity of RAPTA-T and AUF in cancer cells. (a) Structures of RAPTA-T and AUF. (b) Effect of combinations of RAPTA-T with
AUF on cytotoxicity towards A2780 tumour cells (mean±s.d., n¼ 3). (c) CI as a function of drug concentration (additive effect, CI¼0.9–1.1; slight
synergism, CI¼0.7–0.9; synergism, CI¼0.3–0.7; strong synergism, CI¼0.1–0.3; mean±s.d., n¼ 3). (d) Drug uptake into nucleosomes measured by
ICP-MS after treatment with either RAPTA-T or AUF alone or the combination of the two (mean±s.d., n¼ 3).
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Figure 2 | X-ray crystal structure of RAPTA-T–NCP. (a) View of one face of the nucleosome core, with the histone octamer rendered with an electrostatic
potential surface (red, negative; blue, positive). RAPTA-T binds within the extensive electronegative region on the H2A–H2B dimer, known as the
acidic patch. (b) Structure of RAPTA-T-histone adducts. Ruthenium ion-coordinating side chains are labelled. H2A and H2B histone proteins are shown,
respectively, with yellow and salmon coloured carbon backbones. An arrow indicates the van der Waals contact between the carrier ligands of the RU1 and
RU2 adducts.
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crystallographic models—native NCP, RAPTA-T–NCP or
RAPTA-T/AUF–NCP—there are small, but seemingly systematic,
structural alterations associated with histone coordination
of RAPTA-T (Fig. 3d). The perturbations coinciding with
the RAPTA-T adducts appear to extend over some distance,
including to within the immediate vicinity of the nearest
AUF binding site (AU1).
To investigate whether there are systematic alterations in the
structural properties of the nucleosome, which accompany
RAPTA-T adduct formation and promote AUF reactivity, we
conducted molecular dynamics (MD) simulations on four
systems: the native NCP, RAPTA-T–NCP, RAPTA-T/AUF–
NCP and AUF–NCP in aqueous solution. We observe that when
the RAPTA-T adducts are present, the histone octamer undergoes
a series of subtle conformational changes impacting both the
RAPTA-T and AUF binding sites. MD simulations of the
RAPTA-T–NCP and RAPTA-T/AUF–NCP complexes show that
RAPTA-T induces a slight kink (B8) within the long a-helix of
H2A (Fig. 4a; Supplementary Fig. 4; Supplementary Movie 2).
This perturbation of the local environment surrounding the
RAPTA-T adducts occurs in the early steps of dynamics and
is accompanied by further structural alterations. In fact, the
H3 C-terminus (residues 133–135) that had not been resolved in
the crystal structure due to its high mobility undergoes
a conformational transition that culminates in multiple altered
inter-histone contacts around the middle of the histone
octamer (Fig. 4b; Supplementary Figs 5 and 6; Supplementary
Movies 3 and 4). Furthermore, we observe systematic changes
of the relative inter-helical orientations, which involve the
H2A and H3/H30 a-helices and connect them via a network of
subtle structural modifications that link the RU1/RU2 and
the AU1/AU10 adduct sites (Fig. 5). These specific RAPTA-
mediated alterations in the conformation and dynamics of
the histone octamer are seen for both the RAPTA-T–NCP and
RAPTA-T/AUF–NCP systems, but are neither observed for the
native NCP nor the AUF–NCP systems.
As a consequence of the RAPTA-T adduct-mediated
conformational changes, we observe a slight tightening of
the structure at the level of the AUF sites. In fact, by analysing
the nature of the hydrophobic interactions between the histone
elements and the AU1/AU10 adducts, we find that in the
presence of RAPTA-T, AUF forms on average more contacts with
the a-helices of both H3/H30 histones than in the absence of
RAPTA-T (Supplementary Fig. 7; Supplementary Tables 4 and 5).
This indicates that when RAPTA-T adducts are present, histone
substituents tend to make closer, more favourable hydrophobic
contacts with the triethyl groups on the phosphine and
suggests that the AUF binding sites are rendered on average
more compact via the allosteric influence of RAPTA-T binding.
Allosteric mechanism for promoting AUF adduct formation.
To detect the presence of possible dynamic correlations between
the ruthenium and gold binding sites, as well as the molecular
elements that could be responsible for ‘signal transmission’
between them, we performed a cross-correlation analysis.
The cross-correlation matrix calculated for the histone
components of the RAPTA-T/AUF–NCP system (Fig. 6a)
shows a peculiar pattern of correlations, which is absent when
RAPTA-T is not bound (Supplementary Figs 8, 9 and 10). These
correlations describe a path among adjacent a-helices, which
allows the transfer of information from RAPTA-T binding to
the AUF sites. Starting with the kink of the H2A long a-helix
(blue, panel i) that is induced by RAPTA-T binding, we find
a sequence of high correlations among angles between adjacent
a-helices, which connect the RU and AU sites (panels ii–vi).
Indeed, the kink of the H2A long a-helix is highly correlated with
the orientation of the H30 long a-helix (magenta, panel ii;
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Figure 3 | X-ray crystal structure of RAPTA-T/AUF–NCP. (a–c) Structures of AUF and RAPTA-Tadduct sites. H2A, H2B, H3 and H4 histone proteins are
shown respectively with yellow, salmon, cyan and green backbone colouring. (a) Overview of AUF and RAPTA-T binding, illustrating theZ27Å separation
of the two types of adducts. The arrow indicates the pseudo-twofold symmetry axis of the nucleosome. (b) Structure of the AUF-histone adducts.
Dashed lines indicate hydrogen bonding with the H3 H113 imidazole epsilon nitrogen groups. (c) The van der Waals environment of an AUF adduct, shown
in space-filling representation. (d) Superposition of the native NCP (magenta), RAPTA-T–NCP (yellow) and RAPTA-T/AUF–NCP (cyan) models, illustrating
that the structures of the RAPTA-T-containing models are nearly identical, whereas that of the native NCP differs subtly in the vicinity of where the
adducts form.
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Pc¼ 0.86; Fig. 6b; Supplementary Fig. 11), which constitutes the
AU1 binding site on the RAPTA-binding face of the structure.
This latter element is further coupled to the a-helices of the
H3-H30 interface (panel iii), thus reaching the AU10 site at
the opposing face of the structure (Pc¼ 0.83). High couplings are
also associated with the AU1-coordinating H30 helix and
elements of the H4 histone (panel iv) that couple to the central
a-helices of H2A (panel v), which are in turn correlated with H2B
elements (panel vi) and to the kink of the H2A a-helix that is
induced by RAPTA-T binding (panel i).
Given the possibility that the interaction of the two RAPTA-T
adducts with each other could alter the overall dynamics of
the system, or that the presence of both RU1 and RU2 adducts
are required for the observed effect, we also carried out an
additional MD run of the RAPTA-T/AUF–NCP system with the
RAPTA-T adduct at site RU2 omitted. Nevertheless, however, the
B600 ns MD simulation shows that the single RAPTA-T adduct
alone at site RU1 induces as well a kink in the long a-helix
of H2A, like the one observed in the presence of both RU1 and
RU2 RAPTA-T adducts (Supplementary Fig. 12). Furthermore,
the A135 switch, which occurs after B220 ns in the simulation
of the complete RAPTA-T/AUF–NCP system and after B80 ns
for the full RAPTA-T–NCP system, is also observed after
B90 ns in the RU1-only RAPTA-T/AUF–NCP system. Finally,
the calculated cross-correlation matrix reveals a similar correla-
tion pattern as observed in the simulation of the full RAPTA-T/
AUF–NCP and RAPTA-T–NCP systems (Supplementary Figs
10 and 12). This indicates that the impact of RAPTA-T on
altering the conformational dynamics in the nucleosome core
can be achieved by just a single adduct residing in the acidic
patch.
The cross-correlation evidence indicates the critical role of
RAPTA-T in inducing a tight cooperation among the histone
components, which culminates in the transmission of the
allosteric effect to the AUF sites. Taken together, our correlation
analyses indicate that, by inducing a kink in the H2A a-helix,
RAPTA-T promotes the formation of highly correlated motions,
thus allowing communication within the histone core and
resulting in propagation of the effect of RAPTA-T binding to
the AUF sites.
Discussion
Crystallographic studies of proteins treated with different gold
compounds, including triethylphosphine-Au-Cl, have shown
that adducts form at specific histidine sites, in spite of the
presence of thiol sulphur-donor groups22,23. In NCP crystals,
there are at least five solvent accessible histidine imidazole groups
available for metal compound binding14–16, but we only observe
AUF adducts at the one type of histidine site, H113 of H3/H30
(and only when RAPTA-T is bound in the acidic patch). We have
hitherto not observed metal compound binding at this site type,
but these locations are unique in having a small access channel to
the histidine delta nitrogen atom that is composed largely of
hydrophobic histone elements (Fig. 3c). This apparently underlies
the site selectivity of AUF in binding only to this particular motif,
whereby association is fostered through hydrophobic histone
interactions with the triethylphosphine group. Hydrophobic
contacts, and more generally complementarity of shape between
the metal ligands and protein substituents, appear to be
major driving forces behind ruthenium/osmium compound-
histone site selectivity, together with the chemical nature of the
coordinating group(s)14–17.
The enhancement of AUF reactivity towards nucleosome
(chromatin) in the presence of RAPTA-T that we observe in
the NCP crystals as well as in cancer cells is apparently also
a consequence of modulating hydrophobic contacts and shape
complementarity to favour binding, as evidenced by the
MD simulations. The RAPTA-T binding results in dynamic
remodelling of a major portion of the histone octamer in the
nucleosome, which is linked to decreasing the average size of both
of the H3/H30 H113 binding pockets, yielding closer and
more favourable hydrophobic contacts that promote AUF asso-
ciation. This allosteric mechanism behind the RAPTA-T adducts
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Figure 4 | Conformational changes induced by RAPTA-Tadducts. (a) Snapshot from MD simulations of the RAPTA-T/AUF–NCP system, showing a kink
within the long a-helix of H2A induced by the presence of RAPTA-T adducts. The histone proteins (grey) are shown as cartoon, highlighting the kinked
H2A a-helix in orange. The DNA is represented as pale blue ribbons. RAPTA-Tand AUF (black) are shown in space-filling representation. (b) Close view of
the nucleosome core, showing the conformational change involving the H3 C-terminus (A135), which occurs in the presence of RAPTA-T adducts and
culminates in the H-bonding of A135 with H2A K95 and H4 N64. An arrow indicates the conformational change of H3 A135, which is shown as sticks in its
initial (pink) and final (red) configurations. The bottom graph reports the time evolution along MD of the simulated systems for the distance (dA135-switch)
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promoting AUF adduct formation in the nucleosome provides
a rationale for how co-treating cells with the two agents results
in B3-fold higher levels of gold adducts in chromatin relative
to treatment with AUF alone.
Here we have characterized an example of a nucleosome-based
drug–drug synergy as well as a small molecule-mediated allosteric
effect in the nucleosome. There is consistency in our simulation
results since we find effectively the same discrete dynamic
transitions occurring in any of the three NCP systems containing
RAPTA-T adducts (RAPTA-T–NCP, RAPTA-T/AUF–NCP
and RAPTA-T/AUF–NCP with only a single RAPTA-T adduct
at the RU1 site), and we do not observe these conformational
features in either of the systems lacking RAPTA-T adducts
(native NCP and AUF–NCP). In fact, a very recent
MD simulation-based study showed that there are allosteric
networks within the nucleosome core, which can be modulated by
histone variant changes24. Specifically, it was found that
substitution of just four amino acid residues in the histone-fold
loop 1 (L1) region play a dominant role in yielding differential
dynamics and energetics between nucleosomes composed of the
ubiquitous H2A versus the H2A.Z and macroH2A variants.
Moreover, sites of histone posttranslational modification are
disproportionately prevalent at key locations within the allosteric
networks. In conjunction with our findings here, this indicates
that there are likely to be multiple allosteric mechanisms
within the nucleosome, which have the potential to modulate
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ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms14860
6 NATURE COMMUNICATIONS | 8:14860 | DOI: 10.1038/ncomms14860 |www.nature.com/naturecommunications
chromatin activity and can be influenced by even subtle chemical
changes to the histone proteins.
The allosteric mechanism at play could be dependent on the
specific nucleosome binding event or alteration in question,
but may involve one of either two proposed classifications7. In the
‘domino’ model, a sequential set of local events propagates
via a well-defined pathway from one allosteric active site to the
other, spatially distant, site through a network of highly correlated
neighbours. In contrast, with the ‘violin’ model, the binding event
alters a collective vibrational mode of the molecule, transferring
the signal through the whole system without a specific route.
The ‘signal transmission’ we observed here from the ruthenium
to the gold binding sites in the nucleosome core appears to
occur mainly via a domino form of events. Although signal
transmission does not seem to be limited to a single pathway, it is
possible to identify just a few pathways with particularly high
local correlations, in which the binding of RAPTA-T at the
RU1 site induces a local perturbation (kink in the long a-helix
of H2A), creating a defined sequence of correlations among
angles between adjacent a-helices, thereby connecting the RU and
AU sites.
Interestingly, comparison of the stoichiometric gold versus
ruthenium content in chromatin for the RAPTA-T/AUF
co-treatments shows that there is more than a fivefold greater
quantity of gold. In the RAPTA-T/AUF–NCP crystal structure,
there are two equivalents each of ruthenium and gold per
nucleosome. RAPTA-T adducts form on only one face of the
nucleosome, meaning at a single H2A–H2B dimer, as a result
of the symmetry-related (RU10/RU20) sites on the other
H2A–H2B dimer being sterically blocked due to crystal
contacts14. Nonetheless, the MD studies suggest that the
allosteric impact of a RAPTA-T adduct on only one face of the
nucleosome is sufficient to influence both of the AUF binding
sites in a similar fashion. As such, in vivo, it is possible that
RAPTA-T adducted and non-adducted H2A–H2B dimers are
exchanged between different nucleosomes25, which thereby
effectively facilitates AUF adduct formation across chromatin.
This mechanism could explain the excess of AUF equivalents we
observe in the cellular chromatin. Beyond this, adduct occupancy
levels on a given nucleosome in the cell may differ with
respect to the crystallographic studies, where high compound
concentrations are used to ensure acquisition of accurate
structural models. Nevertheless, we have observed that
RAPTA compounds and certain other ruthenium-based agents
form adducts first at the RU1 site14,16, and moreover
occupation of this site alone appears sufficient to elicit the
allosteric effect. This suggests that a single RAPTA-T adduct
per nucleosome would be sufficient to mediate the allosteric
activity in vivo. One additional possibility behind the
disproportionately high gold versus ruthenium levels observed
on the isolated cellular chromatin could relate to AUF adducts
forming at sites outside of the nucleosome core, including for
instance binding to linker histones, which we cannot presently
rule out.
H3′ H4′ H2A′ H2B′ H3 H4 H2A H2B
H
3′
H
4′
H
2A
′
H
2B
′
H
3
H
4
H
2A
H
2B
Protein residue number
AU1 AU1′ RU2RU1
RU2
RU1
AU1′
AU1
800
800
700
600
500
400
300
200
100
0
1
0.8
0.6
0.4
0.2
0
–0.2
–0.4
–0.6
–0.8
Cij
(i)(ii)
(iii)
(iv)
(v)
Pr
ot
ei
n 
re
si
du
e 
nu
m
be
r
(vi)
180°
Pc = 0.88
Pc = 0.83
AU1′
Front Rear
Pc = 0.86
AU1
RU
AU1
RU
H2A
H2B
H3′
H2A
H3′
H3
H3
H4
H4
H2AH2A
H2B0 100 200 300 400 500 600 700
(i) (ii) (iii)
(vi) (v) (iv)
 


 
a
b
Figure 6 | Allosteric mechanism mediating cross-talk between RAPTA-Tand AUF sites. (a) Cross-correlation matrix of the fluctuations of the Ca atoms
(Cij) around their mean positions, calculated over the equilibrium MD trajectory of the RAPTA-T/AUF–NCP system. The extent of correlated (04Cijo1)
and anticorrelated ( 14Cijo0) motions is color-coded according to the scale on the right. RAPTA-T (RU1/RU2) and AUF (AU1/AU10) sites are indicated,
as well as the H2A, H2B, H3 and H4 histones. Highly correlated regions are highlighted within the panels (i–vi). Histone protein components involved
in the (i–vi) correlations are shown on the right. Histones are shown in cartoon representation, with correlated residues highlighted in blue and magenta.
RAPTA-T and AUF are in space-filling representation. (b) Graphical representation of Pearson correlation coefficient (Pc) analysis used to compute the
strength of coupling between the dynamics of the a-helices of the histones for the RAPTA-T/AUF–NCP system. The highest Pc calculated between pairs of
angles formed by the adjacent histone a-helices are reported, revealing a correlation path that connects the H2A a-helix kink, occurring at the RU sites,
with the AUF sites at both the front (AU1) and rear (AU10) of the nucleosome. Blue and magenta dashed lines are used to indicate the correlated angles.
The structure is rotated along the pseudo-twofold axis, showing the front face (left and middle) and rear face (right) of the NCP.
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The synergistic effect of RAPTA-T and AUF in mediating
disproportionately high levels of AUF adducts in cellular
chromatin is consistent with the nucleosome allosteric mechan-
ism we have determined to be in operation in vitro. The
synergistic cytotoxic effect of RAPTA-T/AUF to cancer cells may
also be linked to the higher chromatin adduct levels. It is likely
that the synergy in chromatin adduct formation is at least
partially responsible for the cytotoxicity synergism, since
we observe that pre-treatment of cells with RAPTA-T has
a sensitizing effect on the tumour cells, and it is the RAPTA-T-
chromatin adducts that would have to be initially present to
promote AUF adduct accumulation. Taken together in conjunc-
tion with our previous related studies, this strongly suggests
that adducts on the histone proteins can have a therapeutic
impact14–18, such as the increased tumour cell cytotoxicity
observed here. As we had previously proposed, adducts within
the acidic patch have the potential to interfere directly with
nuclear factor binding and chromatin dynamics and thereby
mediate a cytotoxic effect. In particular, the glutamate residues
involved in coordinating RAPTA-T at the RU1 site are part
of a seemingly ubiquitously employed nucleosome-recognition
motif that binds one or more basic residues of nuclear proteins
that interact with the acidic patch19–21. Therefore, adducts
that form here could inhibit or block the binding of chromatin
associating factors, such as the regulator of chromatin condensa-
tion 1 (ref. 26) and polycomb repressive complex 1 (ref. 27)
proteins (Fig. 7; Supplementary Fig. 13). Although AUF reacts
at sites well outside of the acidic patch, an adduct at either one
or both AU1/AU10 sites also alters the surface properties of
the histone octamer in such a way that could influence factor
binding. In fact, a model based on the structure of the polycomb
repressive complex 1 ubiquitylation module bound to the
NCP places the ubiquitin substrate27 in close proximity with
the AU1/AU10 sites (Supplementary Fig. 14). This suggests that
the AUF adducts could also interfere with nuclear factor
transactions and in conjunction with activities mediated by the
RAPTA-T adduct(s) may underlie at least in part the synergistic
cytotoxic effect we find for the two drugs.
The allosteric mechanism mediating drug–drug synergy we
have characterized in this work suggests that there is untapped
potential for therapeutic modulation of chromatin activity
through exploitation of structural and dynamical features of
the nucleosome. Although we have made the initial discovery
here with metal-based drugs, which are especially favourable
for structural visualization and cellular tracking, it is likely
that synergies and allosteric actions in the nucleosome occur
with other drug classes as well. Moreover, our findings also
suggest that the site targeting and associated activities of drugs
administered individually can differ from those corresponding to
the drug combination. In a broader sense, the structural
and dynamics impact of drug binding to the nucleosome acidic
patch, a chromatin protein binding hot-spot19–21, implies
that analogous histone-mediated allosteric phenomena24 may be
in operation for genomic regulation in vivo. This yields new
possibilities for the potential of nuclear factor binding or histone
posttranslational modifications to alter nucleosome activity over
a distance.
Methods
Metal compounds. The synthesis of RAPTA-T was carried out as previously
described10. Briefly, equimolar amounts of 1,3,5-triaza-7-phosphatricyclo
[3.3.1.1]decane and [Ru(Z6-p-toluene)Cl2]2 were refluxed in methanol, and the
product was precipitated by addition of diethyl ether. The purity of the prepared
product was confirmed through elemental analysis. AUF was purchased from
Alexis Biochemicals (Switzerland).
Crystallographic analysis of treated nucleosome core particle. X-ray
crystallographic analysis of NCP was conducted using nucleosome assembled
with recombinant histones and a 145 bp DNA fragment28. NCP crystals were
grown by the hanging droplet method using buffers of MnCl2, KCl and
K-cacodylate (pH 6.0), and crystals were subsequently stabilized in harvest
buffer (37mM MnCl2, 40mM KCl, 20mM K-cacodylate (pH 6.0), 24%
2-methyl-2,4-pentanediol and 2% trehalose)29. The 37mM MnCl2 buffer
component was subsequently eliminated by gradual replacement with 10mM
MgSO4 followed by thorough rinsing of crystals with the MgSO4-containing
buffer to remove any residual MnCl2 (ref. 14).
The RAPTA-T–NCP crystal structure described in the main text stems from
a 20-h incubation of NCP crystals with 0.25mM RAPTA-T included in the
buffer (Supplementary Table 1; data collected at an X-ray wavelength of 1.50 Å).
The RAPTA-T/AUF–NCP crystal structure described in the main text stems from
a 40-h incubation of NCP crystals with 2mM AUF and 0.5–1mM (22 h at 0.5mM
and 18 h at 1mM) RAPTA-T included in the buffer (Supplementary Table 3; data
collected at an X-ray wavelength of 1.50 Å). Single-crystal X-ray diffraction
data were recorded, subsequent to mounting stabilized crystals directly into the
cryocooling N2 gas stream set at  175 C (ref. 16), at beam line X06DA of the
Swiss Light Source (Paul Scherrer Institute, Villigen, Switzerland) using a Pilatus
detector and X-ray wavelengths of either 1.04 or 1.50 Å. Data were processed with
MOSFLM (ref. 30) and SCALA from the CCP4 package31.
The 2.5 Å resolution crystal structure of NCP containing RAPTA-C
(C¼ cymene) adducts (pdb code 3MNN)14 was used for initial structure solution
by molecular replacement. Structural refinement and model building were carried
out with routines from the CCP4 suite31. Restraint parameters for the adducts
were based on the small molecule crystal structures of AUF (ref. 32) and RAPTA
(refs 33,34) compounds. Data collection and structure refinement statistics are
given in Supplementary Tables 1 and 3. Graphic figures were prepared with
PyMOL (DeLano Scientific LLC, San Carlos, CA, USA).
Cell culture maintenance. Human ovarian A2780 (ECCAC, Salisbury, UK)
cancer cells were cultured in Roswell park memorial institute (RPMI)-1640
medium (Life Technologies, Switzerland) supplemented with 10% foetal bovine
serum (FBS, Sysmex, Horgen, Switzerland). Cells were maintained in a humidified
environment (37 C, 5% CO2).
Sir3PRC1RCC1
E64
E61
H106
E102
RU1
a
b
RU2
RAPTA-T
AUF AUF
AUF
RAPTA-TRAPTA-T
Figure 7 | Potential for RAPTA-T and AUF adducts to interfere with
nucleosome-nuclear factor interactions. (a) Electrostatic potential
(red, negative (–5 kTe–1); blue, positive (þ 5 kTe–1)) of the histone protein
octamer in the native NCP38, highlighting the H2A–H2B acidic patch
(boxed region). A close-up view of the acidic patch is shown in the
inset, emphasizing the central location of the RAPTA-T adducts at sites
RU1 and RU2 in the RAPTA-T/AUF–NCP crystal structure. RAPTA-T
(black C backbone) and coordinating protein residues (cyan C backbone)
are shown as sticks. (b) NCP-on-NCP superpositions of the RAPTA-T/AUF–
NCP crystal structure with those of either the regulator of chromatin
condensation 1 (RCC1)26, polycomb repressive complex 1 (PRC1)27 or
silent information regulator 3 (Sir3)57 chromatin proteins bound to the
NCP (the NCP and the second chromatin factor molecule associated with
the other nucleosome face in the assembly are omitted for clarity).
Chromatin factors (magenta) are shown as ribbons and RAPTA-T and
AUF in space-filling representation.
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Cellular viability assay. Cell viability was determined using the Presto Blue assay.
Cells were seeded in 96-well plates as monolayers with 100ml of cell suspension
(B5,000 cells) per well and preincubated for 24 h in medium supplemented with
10% FBS 37 C and 5% CO2. 100ml of the compound solutions in RPMI medium
containing 10% FBS or RPMI medium containing 10% FBS (for controls) were
added to each well, and the plates were incubated for 72 h. In the case of
combination assays using pre-treatment conditions, the plates were incubated
for 3 h, then the supernatant was aspirated and replaced by 100ml of the respective
other compound solutions and incubated for another 48 h.
Subsequently, Presto Blue was added to the cells (10 ml per well) and the plates
were incubated for 1 h. The fluorescence intensity, directly proportional to the
number of surviving cells, was quantified at ex560 nm/em590 nm using a multiwell
plate reader (Molecular Devices), and the fraction of surviving cells was calculated
from the fluorescence intensity of untreated control cells. Evaluation is based on
the mean from at least two independent experiments, each comprising triplicates
per concentration level.
Analysis of cellular cytotoxicity synergy. Drug-induced cytotoxicity synergy was
analysed with the CompuSyn software (Biosoft, Cambridge, UK), in which the
synergy is expressed as a combination index (CI). The CI method for quantifying
drug cytotoxicity synergism is based on the approach of mass-action law and the
median-effect principle derived from enzyme kinetic models developed by Chou
and Talalay, which has been used extensively to evaluate drug interactions35–37.
In the application of the CI approach, synergism is defined as a combined effect
that is statistically significantly greater than the purely additive effect of the
individual components, whereas antagonism is defined as a combined effect that is
statistically significantly less than the purely additive effect of the individual
components. As such, in the application of this approach, a CI¼ 1 indicates
a purely additive effect, a CIo1 indicates synergy and a CI41 indicates
antagonism. The creators of the CompuSyn software have proposed that CI values
be interpreted as follows: CI41.1, antagonistic effect; CI¼ 0.9–1.1, purely
additive effect; CI¼ 0.7–0.9, mild synergism; CI¼ 0.3–0.7, moderate synergism;
CI¼ 0.1–0.3, strong synergism; and CIo0.1, very strong synergism.
Isolation of cellular chromatin. Cells were grown at 37 C and 5% CO2 in
RPMI 1640 medium containing 10% FBS and 1% penicillin/streptomycin, 150 cm2
flasks to B80% confluency. Then, cells were incubated with RAPTA-T at
a concentration of 500 mM or 20mM auranofin or the combination of both at
37 C for 2 h. Subsequently, the cells were washed with ice-cold phosphate-buffered
saline solution to remove unbound drug and chromatin was extracted using
a Pierce Chromatin Prep Module (Thermo Fisher Scientific, Switzerland) according
to the manufacturer’s protocol. Three independent experiments were performed
for each treatment.
Quantification of cellular DNA. All samples were analysed for their chromosmal
DNA content before ICP-MS measurements. DNA was quantified by the
PicoGreen dsDNA quantitation assay (Invitrogen). PicoGreen (50 ml per well,
200 diluted in 10mM Trisþ 1mM EDTA buffer) was added to 50 ml of
DNA sample and the fluorescence signal was determined by spectrofluorometric
analysis (484 nm excitation/520 nm emission) using an automated reader
(SpectraMax5e, Molecular Devices).
Inductively coupled plasma mass spectrometry measurements. Au, Ru and In
standard solutions (1 g l 1 in 2% HCl, 2% HNO3 and 10% HCl, respectively) were
purchased from CPI International (Amsterdam, The Netherlands). Hydrochloric
acid (37%) at high-purity grade was purchased from Merck (Darmstadt, Germany).
Before determination of ruthenium and gold content, the chromatin extracts
were digested with 400ml of 37% hydrochloric acid solution overnight at room
temperature and adjusted with ultrapure water to a final volume of 4ml. Indium
was added as an internal standard at a concentration of 0.5 ppb. Determinations
of total metal contents were achieved on an Elan DRC II ICP-MS instrument
(Perkin Elmer, Switzerland) equipped with a Meinhard nebulizer and a cyclonic
spray chamber. The ICP-MS instrument was tuned daily using a solution provided
by the manufacturer containing 1 ppb each of Mg, In, Ce, Ba, Pb and U. External
standards were prepared gravimetrically in an identical matrix to the samples
(with regard to internal standard and hydrochloric acid) with single element
standards.
Structural models for computational investigations. Five simulation systems of
the NCP were built: the native form (NCP), with two AUF adducts (AUF–NCP),
with two RAPTA-T adducts (RAPTA-T–NCP), with two AUF and two RAPTA-T
adducts (RAPTA-T/AUF–NCP) and with two AUF and a single RAPTA-T adduct
(RAPTA-T/AUF–NCP, RU1 site only; RU2 adduct omitted). These simulation
systems were based on the crystal structure of the native NCP (PDB code 1AOI,
solved at 2.80Å resolution)38 and the crystal structures of RAPTA-T–NCP and
RAPTA-T/AUF–NCP reported here. Missing residues of the histone proteins in
the RAPTA-T–NCP and RAPTA-T/AUF–NCP structures—consisting of
Ala135 (C-terminus of H3), Lys16–Lys20 (H4), Gly4–Ala14, Lys119 (H2A) and
Lys24–Lys28 (H2B)—were added in conformity with the crystal structure
of the native NCP (ref. 38). Residues from Tyr120 to the C-terminus of the
H2A histone (Lys127) were modelled from the primary sequence using Modeller
9.13 (ref. 39). Each model system was embedded in explicit waters, while
Naþ counter-ions were added to neutralize the total charge, leading to a periodic
box of B160 120 150Å3 and a total number of B313,000 atoms for
each system.
Classical molecular dynamics simulations. Classical MD was used to equilibrate
the aforementioned systems [(1) NCP, (2) AUF–NCP, (3) RAPTA-T–NCP,
(4) RAPTA-T/AUF–NCP and (5) RAPTA-T/AUF–NCP, RU1-only] under
physiological conditions and for the production runs. The AMBER force field
ff99SB2 (ref. 40) with the ff99Bildn3 (ref. 41) modifications was used for the
histone proteins, whereas the parmbsc0 (ref. 42) modification of the AMBER
parm99 force field was adopted for the DNA. The TIP3Pn (ref. 43) model was
employed for the description of explicit waters. Non-standard parameters for
RAPTA-T were taken from previous studies44. The AUF residue was treated
with the general Amber force field45. The bond and angle parameters for the
N–Au–P fragment were obtained from vibrational frequencies after geometry
optimization of the complex at the B3LYP/6-31þG* level, using the relativistic
effective core LANL2DZ pseudopotential for gold. Van der Waals parameters
for Au(I) were taken from Allinger et al.46. The atomic partial charges were
derived following the Merz-Kollman scheme (RESP)47. During the RESP fitting
procedure, the charges of the Ru and Au metal centres and of their coordinating
ligands were fixed to the values obtained from a Bader charge analysis48.
The systems were simulated with a time step of 1–1.5 fs, as detailed below in
the description of the simulations protocol. All simulations were performed
using the Gromacs 4.6.3 code49. The LINCS algorithm50 was used to constrain
covalent bonds involving hydrogen atoms. Long-range electrostatic interactions
were calculated with the particle mesh Ewald method with a real space cut-off of
10 Å. Periodic boundary conditions in the three directions of Cartesian space were
applied. The systems were coupled to a Nose´Hoover thermostat51,52 at a
reference temperature of 310 K and to an isotropic ParrinelloRahman barostat53
at a reference pressure of 1 bar, both with coupling time constants of 1 ps. The
following simulation protocol was adopted for each of the four systems. First, the
systems were subjected to energy minimization using a steepest descent algorithm.
Then, the systems were thermalized to the physiological temperature of 310K
within 1,000 ps. During this phase, a time step of 1 fs was employed. Then,
B8 ns of MD were carried out using a time step of 1 fs, while subsequent runs
were performed using a 1.5 fs time step, following a protocol that we had employed
in our previous studies on ruthenium anticancer agents binding to the NCP
(refs 16,54), as well as to naked DNA44,54.
Approximately 700 ns of MD simulations were collected in the isothermal-
isobaric (NPT) ensemble under standard conditions, for each of the first four
systems, resulting in a total ofB2.8 ms of dynamics. In detail,B750 ns of MD were
carried out for the RAPTA-T/AUF–NCP and RAPTA-T–NCP systems; while
B700 ns of MD were conducted for the RAPTA-T/AUF and the native NCP
systems. Then, the firstB100 ns were removed and analysis was performed on the
subsequentB600 ns of MD, for each simulated system. Finally, to study the effect
of the binding of just a single RAPTA-T molecule, an additional MD simulation of
the RAPTA-T/AUF–NCP system was performed including only a single RAPTA-T
molecule at site RU1. This system was also simulated for a total of B700 ns,
removing the first B100 ns of MD from the analysis. Coordinates of the systems
were collected every 10 ps, for a total ofB70,000 frames for each run. All structural
analyses were performed on the equilibrated trajectories.
Probability distribution analysis. The probability density functions of the angles
between the a-helices, reported in Fig. 5 and Supplementary Fig. 12, were estimated
by using a kernel density estimation. Kernel density estimation is a non-parametric
way to estimate the probability density function of a random variable. A kernel
is a smooth function centred at the location of each data point. The contributions
from each function are summed and plotted. Mathematically, the kernel estimate
f(x) for a data set of N points xi is:
f xð Þ ¼ ð1=NhÞNi K x  xið Þ=hð Þ ð1Þ
where K(x) is any smooth, normalized function, and h is the bandwidth: a measure
of the width of the kernel function. Importantly, the angles between a-helices of the
histone components were calculated considering as a-helical axis the principal axis
of inertia of the Ca atoms of the amino acids forming the helix. Probability density
functions were calculated over the production runs (that is, 600 ns of MD) for all
simulated systems.
Cross-correlation analysis. The cross-correlation matrix Cij between the
fluctuations of the Ca atoms relative to their average positions was used to
identify the coupling of the motions between the protein residues. Cij was
calculated from the last B200 ns of MD simulations of each of the simulated
systems [(1) NCP, (2) AUF–NCP, (3) RAPTA-T–NCP, (4) RAPTA-T/AUF–NCP
and (5) RAPTA-T/AUF–NCP, RU1-only], using equation (2), where Dri and
Drj are the fluctuation vectors of the atoms i and j, respectively. The angle
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms14860 ARTICLE
NATURE COMMUNICATIONS | 8:14860 | DOI: 10.1038/ncomms14860 |www.nature.com/naturecommunications 9
bracket represents an average over the sampled period. The value of Cij ranges
from  1 to 1. Positive Cij values represented a correlated motion between
atoms i and j, while negative Cij values describe anticorrelated motions.
Correlations were calculated from an MD trajectory using the programme
Carma 1.4 (ref. 55).
Cij ¼ DriðtÞ  DrjðtÞ
 
DriðtÞ2
 
DrjðtÞ2
  1=2 ð2Þ
The cross-correlation matrices were calculated from the lastB200 ns of MD for
each system to allow for a consistent comparison among the four different
MD runs (Supplementary Fig. 8). To address the issue of reproducibility and
convergence within the B200 ns time windows reported in Supplementary Fig. 8,
we also calculated the Cij matrix in time windows of B400 ns, and over the entire
production runs (shown in Supplementary Fig. 9). Specifically, the time windows
considered refer to: (i) the last B200 ns of MD; (ii) the last B400 ns of MD and
(iii) the entire production run, comprising B600 ns of MD. Subsequently, the
mean square deviations of the matrix elements (that is, D(Cij)2), as well as the
associated root mean square deviations, were computed, following a testing
procedure that we have employed for other MD simulations on protein/nucleic
acids systems56. As a result, the computed root mean square deviation values range
fromB 0.012 to 0.019, indicating that the MD results are robust and reproducible
within the time frames considered for analysis (Supplementary Fig. 9).
Pearson correlation coefficient analysis. A Pearson correlation coefficient
(Pc) analysis was used to compute the strength of coupling between the a-helices
of the histone components of the different systems studied. Pc are defined as in
equation (3), where X and Y are averages of the time series.
Pc ¼
Pn
i Xi X
 
Yi Y
 
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiPn
i Xi X
 2q ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiPn
i Yi Y
 2q ð3Þ
Pc were calculated between all pairs of angles formed by the histone a-helices and
sorted with respect to increasing correlations Pc (0.6oPco1).
Pc values were calculated between all pairs of angles formed by the histone
a-helices. Then, by considering the highest Pc (0.6oPco1), we detected two
possible pathways that allow the transfer of binding information from the
RAPTA-T (RU) sites to the AUF (AU1/AU10) sites (Supplementary Fig. 11).
Although the highest Pc values track a preferred pathway (Path A, shown in
Fig. 6b), we located an alternative pathway (Path B), which also connects the
kink of the H2A histone with the front and rear of the nucleosome core structure.
Data availability. Atomic coordinates and structure factors for the RAPTA-T–
NCP and RAPTA-T/AUF–NCP models are deposited in the Protein Data Bank
under accession codes 5DNM and 5DNN, respectively. Other data that support the
findings of this study are available from the corresponding authors upon request.
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